Search results
Showing 601 to 650 of 665 results for diabetes
Topic prioritisation
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]
Topic prioritisation
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Discontinued Reference number: GID-TA10375
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]
In development Reference number: GID-TA11377 Expected publication date: TBC
Awaiting development Reference number: GID-TA11945 Expected publication date: TBC
Year Plan for healthcare. Podcasts 30 September 2025 Treating type 2 diabetes with SGLT-2 inhibitors In this episode, we discuss recent...
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development Reference number: GID-TA11373 Expected publication date: TBC
Digital technologies for multidisciplinary weight management
In development Reference number: GID-HTE10077 Expected publication date: TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 18 November 2026
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)
We have moved interventional procedures guidance 787 to become HealthTech guidance 721. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please see NICE's HealthTech guidance 165 for the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE's HealthTech guidance 175 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)
Interventional procedures, IPG257 - Issued: April 2008 --> We have moved interventional procedures guidance 257 to become HealthTech guidance 165. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (IPG518)
We have moved interventional procedures guidance 518 to become HealthTech guidance 371. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE guideline NG28.
This guidance has been updated and replaced by NICE guideline NG28.
Liraglutide for the treatment of type 2 diabetes mellitus (TA203)
This guidance has been updated and replaced by NICE guideline NG28.
This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
Guidance on the use of patient-education models for diabetes (TA60)
This guidance has been replaced by NICE guideline NG17.
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
Health app: GDm-Health for people with gestational diabetes (MIB131)
This health app briefing on GDm-Health for people with gestational diabetes has been withdrawn.
This guidance has been updated and replaced by NICE guideline NG3.
This guidance has been updated and replaced by NICE guideline NG28.
Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)
This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.
Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)
This guidance has been updated and replaced by NICE guideline NG19.
This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).
In development Reference number: GID-TA11352 Expected publication date: TBC
This evidence summary has been updated and replaced by NICE guideline NG28.
Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)
This evidence summary has been updated and replaced by NICE guideline NG17.
This evidence summary has been replaced by NICE technology appraisal guidance 336.
This evidence summary has been updated and replaced by NICE advice ESNM25.
This evidence summary has been updated and replaced by NICE advice ESNM24.
This evidence summary has been updated and replaced by NICE advice ESNM26.
This evidence summary has been updated and replaced by NICE guideline NG28.
This evidence summary has been updated and replaced by NICE guideline NG17.
This evidence summary has been updated and replaced by NICE guideline NG28.
This guidance has been replaced by NICE technology appraisal guidance 63.
This guidance has been updated and replaced by NICE indicator 276.
Diabetes: statins for primary prevention of CVD (40 years and over) (IND183)
This guidance has been updated and replaced by NICE indicator 275.
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This guidance has been updated and replaced by NICE indicator 274.